



Lateral Flow Glyco-Assays for the Rapid and Low-Cost
Detection of Lectins–Polymeric Linkers and Particle
Engineering Are Essential for Selectivity and Performance
Alexander N. Baker, Asier R. Muguruza, Sarah-Jane Richards, Panagiotis G. Georgiou,
Stephen Goetz, Marc Walker, Simone Dedola, Robert A. Field, and Matthew I. Gibson*
Lateral flow immuno-assays, such as the home pregnancy test, are rapid
point-of-care diagnostics that use antibody-coated nanoparticles to bind
antigens/analytes (e.g., viruses, toxins or hormones). Ease of use, no need for
centralized infrastructure and low-cost, makes these devices appealing for
rapid disease identification, especially in low-resource environments. Here
glycosylated polymer-coated nanoparticles are demonstrated for the sensitive,
label-free detection of lectins in lateral flow and flow-through. The systems
introduced here use glycans, not antibodies, to provide recognition: a “lateral
flow glyco-assay,” providing unique biosensing opportunities. Glycans are
installed onto polymer termini and immobilized onto gold nanoparticles,
providing colloidal stability but crucially also introducing assay tunability and
selectivity. Using soybean agglutinin and Ricinus communis agglutinin I
(RCA120) as model analytes, the impact of polymer chain length and
nanoparticle core size are evaluated, with chain length found to have a
significant effect on signal generation—highlighting the need to control the
macromolecular architecture to tune response. With optimized systems,
lectins are detectable at subnanomolar concentrations, comparable to
antibody-based systems. Complete lateral flow devices are also assembled to
show how these devices can be deployed in the “real world.” This work shows
that glycan-binding can be a valuable tool in rapid diagnostics.
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Lateral flow devices (LFDs), such as the
home pregnancy test,[1] can be used to pro-
vide rapid point of care testing at low cost.
The cost-effectiveness and clinical useful-
ness of LFDs has been well demonstrated
by malaria rapid diagnostic tests,[2,3] in the
diagnosis of cutaneous leishmaniasis[4] and
in comparisons with reverse transcription
polymerase chain reaction (RT-PCR) ap-
proaches for Ebola diagnosis.[5] More re-
cently LFDs have been used to detect SARS-
COV-2, as rapid and low-cost diagnostics
allowing for early detection when deployed
appropriately.[6] LFDs are chromatographic
paper-based devices which function by flow-
ing the analyte past a functionalized sta-
tionary phase with affinity for the ana-
lyte. As the analyte passes through the
device it is bound by both the stationary
phase and the signal generating mobile
phase, most commonly gold nanoparticles
(AuNPs) functionalized with receptors for
the analyte, “sandwiching” the analyte.[7]
This leads to a visible color forming at the
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test line, indicating a positive test. AuNPs are the most
commonly[7] used mobile phase due to their strong coloration
associated with their localized surface plasmon resonance
band,[8–10] and ease of functionalization by nonspecific surface
passivation (e.g., absorption of proteins), or through aurophilic
functionalities such as thiols. AuNPs are also easy to synthe-
size by reduction of gold salts. Notably, other signal generating
units such as; quantum dots,[11] graphene oxide,[12,13] and carbon
nanotubes[14] have also been used in LFDs.
Typically, the capture units for the analyte, on both the test
line and nanoparticle surface, are antibodies, owing to their
high affinity and selectivity. However, antibodies are not essen-
tial components in LFDs. Other recognition units such as; nu-
cleic acids,[15] lectins,[16] and glycans can also be used, so long as
the analyte is bound with sufficient affinity and specificity. Gly-
cans are ubiquitous in biological systems[17] with over half of all
mammalian proteins estimated to be glycosylated[18] and glyco-
conjugates playing a variety of roles from cell signaling[19] to me-
diating immune responses.[20] They are also the site of pathogen
adhesion during many viral infections,[21,22] especially respiratory
viruses such as influenzas.[23]
The diverse range of biological recognition processes driven
by glycans presents many opportunities to either target the gly-
cans themselves or the proteins that sense for them (lectins)
in biosensing or diagnostic applications. Lectins are found
in a wide-array of environments, for example the cholera
toxin,[24] ricin,[25] lectins in snake venoms[26] and as biocides
in algae.[27] Furthermore, lectins have been used for decades
as histological stains, to identify diseased tissue based on
glycosylation,[28] while lectin-containing biosensors have been ex-
tensively reviewed.[29–31] Damborský et al. have reported a LFD
that utilizes immobilized lectins (in place of antibodies) as test
lines for prostate specific antigen,[16,32] and Bayoumy et al. have
used antibodies to target glycans.[33] However, to the best of our
knowledge, there are very few examples of the exploration of
glycans as the detection units in lateral flow, that is, using gly-
cans to sense for an analyte—rather than targeting glycans as
an analyte or a glycosylated analyte. A mannose-functionalized
p-acrylamidophenyl polymer-coated AuNP, with an antibody as
the test line, was used by Ishii et al. to detect Concanavalin A
(ConA) in a LFD.[34] We believe this is the first report of gly-
cans forming part of an LFD. Miura and coworkers built on this
work further by preparing a small panel of glycopolymer func-
tionalized AuNPs for the detection of ConA—again using an an-
tibody as the stationary phase.[35] These two examples demon-
strated that glyco-nanoparticles could be deployed in LFDs, how-
ever, both reports relied on using antibodies in part, and were
only demonstrated against the plant lectin ConA. Baker et al.,
discovered that SARS-COV-2 (the causative agent of COVID-19)
spike protein has affinity toward sialic acids,[36] as had been re-
ported for previous coronaviruses[37,38] including the coronavirus
that causes Middle East respiratory syndrome.[39] Using N-acetyl
neuraminic acid-terminated polymer ligands, immobilized onto
AuNPs, it was demonstrated that a SARS-COV-2 spike protein
bearing pseudovirus could be detected in a lateral flow glyco-
assay (using a BSA-glycoconjugate test-line), and that a flow-
through assay (LFD without a test line) device could be used for
the detection of S1 spike protein.[36] This clearly demonstrated
that lateral flow glyco-assays, LFDs that use glycans as capture
agents (on the test line and particle) for an analyte, have poten-
tial applications in rapid diagnostics, surveillance, and as acces-
sible research tools for evaluating glycan-binding protein func-
tion. Further work utilizing a flow-through glyco-assay demon-
strated that glycans could be used as capture agents to sense for
the SARS-COV-2 virus in patient samples and that these tests
were thermally robust,[40] which could be an advantage of glycan-
based devices versus antibody-based devices.[41] To advance the
study of glyco-LFD technology, LFDs that use glycans as capture
agents on test lines and/or particles, it is crucial to understand
how each component (particle, surface) impacts performance.
Herein, we explore how the role of polymer chain length, gly-
can density, and nanoparticle size affect the performance of lat-
eral flow glyco-assays, for the detection of lectin analytes, as a
model system to further validate glyco-LFDs. This study reveals
that the outputs (signal, nonspecific binding, and background)
were dependent on the nanoparticle’s structural parameters. In
particular, the precise chain length of the polymeric tether re-
quired for optimal detection of different lectins (soybean agglu-
tinin [SBA] and RCA120 [Ricinus communis agglutinin I]) was
shown to be different. This provides the opportunity to introduce
selectivity not just through the glycan, but also through macro-
molecular engineering, which is a unique feature of this technol-
ogy. Guided by these results, complete diagnostic devices were
fabricated and used to detect SBA in 10 min at concentrations as
low as 5 μg mL−1.
2. Results and Discussion
The primary aim of this work was to develop lateral flow
technology to enable the sensitive detection of lectins, using
glycosylated polymer-stabilized AuNPs, as an alternative to
traditional antibody-based detection systems. To achieve this,
an understanding of how particle/polymer structure impacts
lateral flow performance was required. Therefore, a library-based
screening approach was undertaken, with SBA chosen as the
model lectin for detection. The precise chain length, surface gly-
can density, and particle size have been previously shown to be
crucial in plasmonic (aggregation) glyco-assays, by modulating
particle/analyte interactions and outcomes, while also ensuring
colloidal stability in complex media.[42,43] Reversible addition–
fragmentation chain transfer (RAFT) polymerization was used
to synthesize a panel of poly(hydroxyethyl acrylamide)s (PHEA)
using pentafluorophenyl-2-(dodecylthiocarbonothioylthio)-2-
methylpropanoate (PFP-DMP) as the RAFT agent to install a
pentafluorophenyl group at the 𝜔-chain end, and a protected
thiol at the 𝛼-end (for AuNP immobilization), Figure 1. PHEA
was chosen because of its solubility and colloidal stability when
immobilized onto AuNPs.[44] The polymers were characterized
(Table 1) by size exclusion chromatography (SEC, Figure 1C)
showing low dispersity values, and the structure confirmed by
1H, 13C, and 19F NMR (Supporting Information). Galactosamine
(2-deoxy-2-amino-galactose) was conjugated to the polymer by
displacement of the PFP end-group, to mimic the structure of
N-acetylgalactosamine (GalNAc) due to formation of the amide
linkage. Glycan addition was confirmed by FTIR, 19F, and 1H
NMR. Non-glycosylated polymers were produced by reaction
with n-pentylamine and used (below) to dilute the density of
glycans on the particle surface.
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Figure 1. Synthesis of gold nanoparticle library functionalized with glycan-terminated polymeric tethers at various densities. A) Polymerization of N-
hydroxyethyl acrylamide (HEA) by RAFT, followed by displacement of the PFP ester with amino-glycans. B) Assembly of polymers onto preformed gold
nanoparticles to give variable glycan densities. C) Normalized size exclusion chromatography analysis of PHEA polymers from Table 1. D) C 1s x-ray
photoelectron spectrum of 100% GalPHEA72@AuNP16. E) Graphical representation of AuNP library illustrating the three variables of diameter, coating
DP, and glycan density.
Table 1. Polymers prepared for detecting SBA.











PHEA26 10 1700 3600 4100 1.17
PHEA40 20 2800 5100 5000 1.19
PHEA72 40 5100 8900 8600 1.28
PHEA110 70 8600 13 000 14 000 1.27
a)Calculatedfromthefeedratio of monomer to chain transfer agent
b)
Calculated against poly(methyl methacrylate) standards using 5 mm NH4BF4 in DMF as eluent
c)
Determined
from 1H NMR end-group analysis
Adv. Healthcare Mater. 2021, 2101784 2101784 (3 of 11) © 2021 The Authors. Advanced Healthcare Materials published by Wiley-VCH GmbH
www.advancedsciencenews.com www.advhealthmat.de
Citrate stabilized 16 and 40 nm AuNPs were synthesized by
a seeded growth approach and characterized by dynamic light
scattering (DLS), transmission electron microscopy (Figure S12,
Supporting Information), and UV–vis analysis.[45,46] The AuNPs
were then functionalized with varying ratios of glycosylated and
non-glycosylated polymers to produce 100%, 66%, 33%, and
0% glycan-densities on the AuNPs for each polymer length and
AuNP size, to produce a library of 34 particles (including the
two citrate-stabilized AuNPs), Figure 1. UV–vis spectroscopy and
DLS confirmed functionalization (Figures S13–S21 and Table
S1, Supporting Information). In some cases, the particles were
unstable (fully aggregated): all GalPHEA26@AuNP40’s and all
GalPHEA40@AuNP40’s except 100% sugar functionalized; hence
these particles were excluded from further analysis. It is worth
noting that a hydrophobic amine was used in place of the gly-
can for the nonglycosylated polymers (to remove the PFP group)
which contributes to the observed aggregation. A hydrophobic
amine was chosen as some aggregation of the particles with both
antigen and test line in an LFD may aid detection, and therefore
even the dispersed samples showed some populations of larger
particles in the DLS (see Supporting Information) but were all
suitable for this screening step. Therefore, this does not prevent
their application here where the LFD performance is the primary
outcome. To further characterize the surface of the particles, x-
ray photoelectron spectroscopy (XPS) was conducted on dried
particles (Figures S36–S46 and Tables S15 and S16, Supporting
Information). XPS confirmed the presence of amide (C(O)NC)
and amine (C(O)NC) peaks in the C 1s (Figure 1D), and in the
N 1s scans (amine and amides have similar/overlapping binding
energies so were not distinguishable), showing the presence of
the PHEA, which were not present in the naked AuNP samples.
Similarly, ether (XPS cannot easily distinguish ether from alcohol
and are combined in the model employed here) peaks in the C 1s
scans were far larger in samples containing 100% sugar than in
the citrate-stabilized AuNPs with no polymer functionalization.
It is important to note the presence of carbonyls and carboxylic
acid carbons are from atmospheric contaminants, and the pres-
ence of carbide likely from the silicon wafer particle interface.
With this library of glycoparticles to hand, their function
was screened in a lateral flow assay. Figure 2 shows the set-
up of the assay. A dipstick was made, where the test line (to
capture the lectin analyte) was made by depositing 1 μL of
1 mg mL−1 Galɑ1-3Gal𝛽1-4GlcNAc-bovine serum albumin con-
jugate (Galɑ1-3Gal𝛽1-4GlcNAc-BSA) which has affinity for SBA
(Figure 2A). For this evaluation no control line was employed,
which would be essential for a real diagnostic to demonstrate a
device is functioning (and is used in the final devices at the end of
this study, below).[47] The mobile phase was SBA (0.05 mg mL−1,
≈0.4 nmol mL−1) and OD = 1 (optical density at UVmax, the stan-
dard measurement for concentration) AuNPs (Figure 2D). No-
tably the OD used was kept constant (OD = 1) for all dipsticks
and devices to provide a constant concentration across and be-
tween assays allowing for easy comparison. Negative controls
were run of the AuNPs versus Galɑ1-3Gal𝛽1-4GlcNAc-BSA only
(Figure 2C) and unfunctionalized BSA only (Figure 2B) test lines
to determine if any off-target binding to the test line itself oc-
curred. Further negative controls were run using AuNPs versus
Galɑ1-3Gal𝛽1-4GlcNAc-BSA test lines with Ulex Europaeus Ag-
Figure 2. Schematic of dipstick lateral flow assay. A) Design of dipstick.
B) Lateral flow with unfunctionalized BSA where particles flow without en-
gaging the test line. C) Lateral flow with Galɑ1-3Gal𝛽1-4GlcNAc-BSA test
line and no analyte; particles do not engage test line. D) Lateral flow with
Galɑ1-3Gal𝛽1-4GlcNAc-BSA test line and SBA (analyte) resulting in cap-
ture and signal generation. E) Lateral flow with Galɑ1-3Gal𝛽1-4GlcNAc-
BSA test line and UEA (negative control), hence no signal generation.
glutinin I (UEA, 0.05 mg mL−1, Figure 2E), a lectin with no affin-
ity for GalNAc.
All dipsticks were run in triplicate for 20 min before being
scanned and analyzed with image analysis software[48] to evaluate
binding (photographs and image analysis of all strips are in the
Tables S2–S12 and Figures S22–S32, Supporting Information).
This process of running in triplicate and averaging (mean) the
data was carried out for all dipsticks and devices in this study. The
test line is situated on the strip around 15 to 35 relative distance
units (i.e., x-axis output from image analysis) along the strip, not-
ing that the strip length is set to 100 relative distance units. An
example of positive (with SBA as analyte) and negative (buffer
alone) dipsticks are shown in Figure 3A, with the direction of
flow, test line area, and the wick area labeled. The wick area is
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Figure 3. Optimization of the gold nanoparticle in dipstick format using
SBA as the analyte. A) Example lateral flow dipsticks showing test line
(Galɑ1-3Gal𝛽1-4GlcNAc-BSA, 1 mg mL−1) and direction of flow. B) Ex-
ample image analysis result using 100% GalPHEA72@AuNP16. C) Sum-
mary of selected nanoparticle performance from image analysis. Signal
to noise ratio is indicated above each pair of bars. Images shown have
been enhanced for clarity and all original dipstick photos and image anal-
yses are included in the Supporting Information. Test lines for (B) are un-
functionalized BSA (BSA, 1 mg mL−1), and Galɑ1-3Gal𝛽1-4GlcNAc-BSA
(BSA-Gal, 1 mg mL−1) with (or without) lectins in solution (SBA or UEA,
0.05 mg mL−1).
where unbound nanoparticles gather (at the end of the assay) and
is typically “hidden” in the housing of a full lateral flow cassette.
An example image analysis of these dipsticks is shown in Fig-
ure 3B and a summary of the best performing systems is show in
Figure 3C. Full analysis of all strips as a function of nanoparticle
composition and original images are included in the Supporting
Information.
Consideration of the data revealed three trends; i) as poly-
mer length increases the total amount of binding to SBA de-
creases, but the nonspecific binding in negative controls was
also reduced; ii) decreasing the density of the glycan on the
particles decreases binding to SBA but also leads to some in-
creases in nonspecific binding; and iii) increasing AuNP diam-
eter led to increased signal intensity but also increased noise
from the background. Taking this into account, the particles
that gave optimal performance against SBA were 100% glycan-
functionalized GalPHEA72@AuNP16 and GalPHEA72@AuNP40.
While GalPHEA110@AuNP40 gave higher signals, the back-
ground signal was also very high. These three particle sys-
tems were further analyzed by considering their signal to noise
ratios (Figure 3C, and Figures S27 and S32 and Tables S7
and S12, Supporting Information); 100% glycan-functionalized
GalPHEA72@AuNP16 was found to have the highest signal to
noise ratio despite producing less signal than 100% glycan-
functionalized GalPHEA72@AuNP40.
There are limited examples of lateral flow assays based only
on glycans, but in our previous report of a system for SARS-
COV-2 detection, larger nanoparticles (35 nm) were optimal.[36]
This highlights how each system can be fine-tuned to the detec-
tion challenge, with this data illustrating how tuning the particle/
polymer/ligand interfaces enables modulation of the observable
outputs. Notably buffer conditions, and materials used in the
LFD were kept constant in this work but could also be further
optimized to modulate output.
The identified optimum particle, 100% glycan-functionalized
GalPHEA72@AuNP16, was next explored for its limit of detection
(LoD) in the dipstick assays. A serial dilution of SBA was prepared
in the buffer and run, Figure 4 (Table S13 and Figure S33, Sup-
porting Information). The LoD was found to be 0.02 mg mL−1
(0.17 nmol mL−1). This is similar to a commercial pregnancy test
(≈0.7–0.07 nmol mL−1)[49] showing that glycans can achieve the
necessary LoD to be a viable alternative/companion, to antibody-
based LFDs. It should be noted that no attempts to reduce back-
ground (via buffer tuning) were made here, but a lower back-
ground was achieved in the final device (below).
The above data showed that the lateral flow glyco-assay ap-
proach can be used to detect SBA and that the exact nanoparticle
used (size, coating, and density of ligands) can be easily tuned
and is a key determinant in their output. Therefore, another lectin
was also explored, RCA120, which has affinity toward galactose
and GalNAc.[50,51] PHEA40, PHEA72, and PHEA110 were function-
alized with 1-deoxy-1-amino-galactose due to known affinity of
this isomer toward RCA120 (Note, this is a different galactosamine
isomer than used for the SBA study above). Shorter polymers,
less than 100% sugar functionalization and 40 nm AuNPs were
not explored based on the experiments with SBA where there was
significant particle aggregation.
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Table 2. Additional polymers prepared for detecting RCA120.











PHEA50 25 3400 6400 5500 1.27
PHEA58 30 4000 7200 6700 1.26
a)
Calculated from the feed ratio of monomer to chain transfer agent
b)
Calculated from SEC using poly(methyl methacrylate) standards
c)
Determined from 1H NMR end-group
analysis
Figure 4. Lateral flow data from SBA dipstick assays to determine limit of
detection. A) Lateral flow dipsticks run with the indicated concentrations
of SBA using 100% GalPHEA72@AuNP16. B) Analyzed lateral flow inten-
sity data from the lateral flow strips in A.
It was not possible to find a commercially available BSA-
glycoconjugate with sufficient affinity for RCA120 to generate
a test line. Therefore, an alternative approach, a “flow-through
assay,”[40,52,53] was used based on direct deposition of the tar-
get (RCA120 at 5 mg mL
−1) onto the test line, followed by run-
ning the dipstick. Whilst unconventional, we have previously
used this methodology in S1 spike protein detection.[36] The
dipsticks were run in the same manner as the SBA system
and the results are summarized in Figure 5. In addition to
RCA120 the following controls were tested; Wheat Germ Agglu-
tinin (WGA) at 5 mg mL−1, a lectin with known affinity for N-
acetyl-glucosamine,[54] used to assess off-target binding; Galɑ1-
3Gal𝛽1-4GlcNAc-BSA at 1 mg mL−1, used to determine if a BSA
glycoconjugate may serve as a viable test line in the future; and
SBA at 5 mg mL−1. SBA was used as it has a known affinity
to galactose residues,[55] providing a challenge to design a flow-
through assay that only generates signal against RCA120. All im-
ages and analysis are available in the Figure S49 and Table S18,
Supporting Information.
In contrast to what was observed with SBA, the aver-
aged triplicate dipstick data for GalPHEA40@AuNP16 (Fig-
ure 5A) showed binding to RCA120 (and SBA) while the longer
polymer PHEA72 (Figure 5B) showed very weak binding to
RCA120 only (GalPHEA110@AuNP16 [Figure 5C] showed no
clear binding to any lectins or controls). Notably 2-deoxy-2-
amino-GalPHEA72@AuNP16 (Figure 5D) showed binding to
both RCA120 and SBA but gave a stronger signal with SBA. This
further shows that the optimal presentation of the glycan for each
lectin is subtly different; but offers opportunities for tuning selec-
tivity and affinity. Two additional polymers were therefore syn-
thesized to fall between the 40–72 range of chain lengths already
tested, to improve the assay, Table 2.
The two additional polymers, PHEA50 and PHEA58 (Ta-
ble 2) were functionalized with 1-deoxy-1-amino-galactose,
immobilized onto 16 nm AuNPs, as described above, and fully
characterized (Tables S17, S20, and S21 and Figures S47, S48,
S52, and S57, Supporting Information). Subsequent evaluation
in the same dipstick format found both bound to RCA120, gen-
erating positive test lines. Whilst both AuNPs were bound to
the RCA120, the GalPHEA58@AuNP16 generated significantly
weaker signal intensity against SBA and WGA controls (Figure
6B) compared to GalPHEA50@AuNP16 (Figure 6A). This con-
firmed that precision tuning the polymer chain length enables
control of the overall signal generated and can provide additional
discriminatory power to the assay. The identified optimum
particle, 100% glycan-functionalized GalPHEA58@AuNP16, was
next explored for its LoD in the dipstick assay. A serial dilution of
RCA120 was prepared and deposited onto the strips (Figure 6C,D,
and Table S19 and Figure S50, Supporting Information). The
lowest concentration that could be detected, above the signal
of a 5 mg mL−1 SBA control, was found to be 0.5 mg mL−1
(4.2 nmol mL−1).[56]
The dipsticks used above demonstrate the principle of lateral
flow and flow-through glyco-assays for detecting lectins. How-
ever, a full device in a cassette format is required for a diagnos-
tic which can be packaged, stored, distributed, and used easily.
Therefore, cassettes designed to detect SBA (for which valid test
and control lines were available) were assembled as proof of prin-
ciple and prototype for a complete lateral flow glyco-assay for
lectin detection.
2-deoxy-2-amino-GalPHEA72@AuNP16 was selected as the
optimal particle setup (from above), so particles were dried onto
conjugate pads (from which they are released when the analyte
solution is applied) and integrated into a complete cassette. A
control line of 1 μL (5 mg mL−1) SBA was also added to the
cassettes. A control line is essential in a functioning device to
prove the device is running correctly (e.g., to distinguish be-
tween a negative result, and one where the particles did not flow)
but was not used in the screening experiments above. Design
schematics (Figure 7) and images of complete cassettes are
shown in Figure 8 (and in full detail in the Figure S35 and Table
S14, Supporting Information). Using this set up, concentrations
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Figure 5. Analyzed flow-through data from RCA120 screen and inset are example dipstick photos. A) GalPHEA40@AuNP16; B) GalPHEA72@AuNP16;
C) GalPHEA110@AuNP16; D) 2-deoxy-2-amino-GalPHEA72@AuNP16. Test lines were RCA120, SBA, or WGA at 5 mg mL
−1, or BSA-Gal = Galɑ1-3Gal𝛽1-
4GlcNAc-BSA at 1 mg mL−1.
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Figure 6. Flow-through dipstick assays against RCA120. A) Data
from GalPHEA50@AuNP16 and inset example dipsticks. B)
Data from GalPHEA58@AuNP16 and inset example dipsticks. C)
GalPHEA58@AuNP16 dipstick assays to determine limit of detection of
RCA120. D) Analyzed limit of detection data of GalPHEA58@AuNP16
for RCA120. Test lines for (A) and (B) were RCA120, SBA, or WGA at
5 mg mL−1; or BSA-Gal = Galɑ1-3Gal𝛽1-4GlcNAc-BSA at 1 mg mL−1.
of SBA as low as 5 μg mL−1 (0.042 nmol mL−1) could be detected
in the buffer in 10 min (Figure 8). The drop in binding at 0.03
and 0.02 mg mL−1 indicates the difficulty in scanning the cas-
settes (when visually compared to the strips after removal from
the devices, Table S14, Supporting Information) and variability
between the hand-made devices. Notably all devices in the tripli-
cates produced an observable signal and when averaged gave the
values presented in Figure 8. In summary, Figure 8 validates the
principle of the lateral flow glyco-assay, which can be adapted to
other glycan-binding antigens, such as toxins or viruses. In each
cassette a control line was also visible, confirming the devices ran
correctly.
Figure 7. Schematic of complete cassette lateral flow for SBA binding and
inlaid images of example cassettes. A) Labeled schematic of cassette. B)
Lateral flow with SBA target in sample buffer. C) Lateral flow with no pro-
tein in buffer.
Figure 8. Lateral flow data from SBA cassette assays after 10 min to deter-
mine limit of detection. A) Example lateral flow cassette photographs for
varying concentrations of SBA. B) Analyzed lateral flow intensity data for
varying concentrations of SBA.
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3. Conclusions
Here the emerging concept of lateral flow glyco-assays, as a tool
for rapid diagnostics/sensing of glycan-binding analytes is vali-
dated. Polymeric ligands were used to install glycans onto AuNPs
(which are the signal generating units) and provide both colloidal
stability in solution while ensuring that the particles resuspend
and flow in the LFDs. A library of polymer linker lengths (syn-
thesized using RAFT polymerization), glycan density (by using
polymers without glycans), and nanoparticle size was assembled
and the impact of each feature on performance evaluated. A cru-
cial observation was that the optimal polymer-coating required
for the detection of SBA was not the same as required for RCA120.
This is a unique advantage of employing the polymeric tethers,
in that the final device’s performance and specificity can be tuned
by macromolecular engineering, in addition to varying the exact
glycan used. In general, too short polymers increase nonspecific
binding, longer polymers reduced nonspecific binding but could
reduce signal intensity also, while larger gold particles increase
the signal of both nonspecific and specific binding. Therefore,
tuning is essential to ensure that accurate and specific diagnos-
tics can be developed.
The optimized glyconanoparticles were incorporated into
“real” lateral flow cassettes, that is, a single device where a so-
lution of analyte is applied to a well and run without any addi-
tional machine/user interfaces. Using this setup, SBA could be
detected as low as 5 μg mL−1 (0.042 nmol mL−1) which is below
the (molar) detection limits of commercial lateral flow pregnancy
tests which use antibody-functionalized AuNPs and falls within
the range of values (microgram to nanogram per milliliter) for
antibody-based LFDs.[57] Taken together, this work demonstrates
the power of using glycans in easy to use, disposable, paper-based
lateral flow glyco-assay diagnostics. By using glycans it is possible
to probe function (e.g., is the antigen folded) and may provide op-
portunities for monitoring pathogenic state, rather than simply
identifying if a pathogen is present.
4. Experimental Section
Materials: All chemicals were used as supplied unless otherwise
stated. N-Hydroxyethyl acrylamide (97%), 4,4′-azobis(4-cyanovaleric acid)
(ACVA, 98%), 4-dimethylaminopyridine (>98%), mesitylene (reagent
grade), triethylamine (>99%), sodium citrate tribasic dihydrate (>99%),
gold(III) chloride trihydrate (99.9%), ammonium carbonate (reagent
grade), potassium phosphate tri basic (≥98%, reagent grade), potassium
hexafluorophosphate (99.5%), deuterium oxide (D2O, 99.9%), deuterated
chloroform (CDCl3, 99.8%), diethyl ether (≥99.8%, ACS reagent grade),
methanol (≥99.8%, ACS reagent grade), toluene (≥99.7%,), Tween-20
(molecular biology grade), HEPES, PVP40 (poly(vinyl pyrrolidone)400
[Average Mw ≈ 40 000]), sucrose (Bioultra grade), carbon disulfide
(≥99.8%), acetone (≥99%), 1-dodecane thiol (≥98%), n-pentylamine
(99%), and pentafluorophenol (≥ 99%, reagent plus) were purchased
from Sigma-Aldrich. Anhydrous trehalose was purchased from Alfa Ae-
sar. DMF (>99%) and 2-bromo-2-methyl propionic acid (98%) were
purchased from Acros Organics. Galactosamine HCl and 1-ethyl-3-
(3-dimethylaminopropyl)carbodiimide hydrochloride (>98%), were pur-
chased from Carbosynth. HPLC grade acetonitrile (≥99.8%), glucose (lab-
reagent grade), hexane fraction from petrol (lab reagent grade), DCM
(99% lab reagent grade), sodium hydrogen carbonate (≥99%), ethyl ac-
etate (≥99.7%, analytical reagent grade), sodium chloride (≥99.5%), cal-
cium chloride, 40–60 petroleum ether (lab reagent grade), hydrochloric
acid (≈37%, analytical grade), glacial acetic acid (analytical grade), and
magnesium sulfate (reagent grade) were purchased from Thermo Fisher
Scientific.
Nitrocellulose Immunopore RP 90–150 s/4 cm 25mm was purchased
from GE Healthcare. Lateral flow backing cards 60 mm by 301.58 mm (KN-
PS1060.45 with KN211 adhesive) and lateral flow cassettes (KN-CT105)
were purchased from Kenosha Tapes. Cellulose fiber wick material 20 cm
by 30 cm by 0.825 mm (290 gsm and 180 mL min−1) (Surewick
CFSP223000) was purchased from EMD Millipore. Glass fiber conjugate
pads (GFCP103000) 10 mm by 300 mm and unfunctionalized BSA were
purchased from Merck. Thick chromatography paper (for sample pads),
Grade 237, Ahlstrom 20 cm by 20 cm was purchased from VWR Interna-
tional.
SBA, Ricinus Communis Agglutinin I (RCA120), Ulex Europaeus Agglu-
tinin I, and WGA were purchased from Vector Laboratories. Galɑ1-3Gal𝛽1-
4GlcNAc-BSA (3 atom spacer, NGP0334) was purchased from Dextra Lab-
oratories.
Ultrapure water used for buffers was MilliQ grade 18.2 mΩ resistance.
Representative Polymerization of 2-Hydroxyethyl Acrylamide: PHEA40
as representative example. 2.0 g (17.37 mmol) of 2-hydroxyethyl acry-
lamide, 0.043 g (0.15 mmol) of ACVA, and 0.368 g (0.69 mmol) of
PFP-DMP was added to 16 mL 1:1 toluene:methanol and degassed with
nitrogen for 30 min. The reaction vessel was stirred and heated to 70 °C
for 2 h. The solvent was removed under vacuum. The crude product was
dissolved in the minimum amount of methanol. Diethyl ether cooled
in liquid nitrogen was added to the methanol to form a precipitate. The
mixture was centrifuged for 2 min at 13 krpm and the liquid decanted off.
The solid was dissolved in methanol and removed under vacuum to give
a yellow crystalline solid.
PHEA40 — 𝛿H (300 MHz, D2O) 8.35–7.95 (21H, m, NH), 3.97–3.56
(78H, m, NHCH2), 3.56–3.03 (80H, m, CH2OH & SCH2), 2.41–1.90
(41H, m, CH2CHC(O) & C(CH3)2), 1.90 – 0.99 (108H, m, CH2CHC(O)
& CH2CH2CH2CH2CH2CH2CH2CH2CH2CH2CH3), 0.83–0.72 (5H, m,
CH2CH3); 𝛿F (300 MHz, D2O) −152.0– −164.3 (5F, m, C6F5). FTIR (cm–1)
– 3263 (OH, broad), 3088 & 2924 (C(O)NH and NH), 1638 & 1541
(C(O)NH) Yield – 73%
PHEA26 — 𝛿H (300 MHz, D2O) 8.38–7.88 (13H, m, NH), 3.96–3.54
(55H, m, NHCH2), 3.55–3.09 (78H, m, CH2OH & SCH2), 2.53–1.90
(31H, m, CH2CHC(O) & C(CH3)2), 1.90–1.01 (86H, m, CH2CHC(O)
& CH2CH2CH2CH2CH2CH2CH2CH2CH2CH2CH3), 0.84–0.73 (5H, m,
CH2CH3)
PHEA50 — 𝛿H (300 MHz, D2O) 8.31–7.97 (23H, m, NH), 3.99–3.55
(86H, m, NHCH2), 3.55–3.09 (100H, m, CH2OH & SCH2), 2.49–1.90
(46H, m, CH2CHC(O) & C(CH3)2), 1.90–0.98 (110H, m, CH2CHC(O)
& CH2CH2CH2CH2CH2CH2CH2CH2CH2CH2CH3), 0.84–0.72 (5H, m,
CH2CH3)
PHEA58 — 𝛿H (300 MHz, D2O) 8.36–7.98 (29H, m, NH), 4.00–3.55
(H, 108H, m, NHCH2), 3.55–3.15 (127H, m, CH2OH & SCH2), 2.36–1.88
(56H, m, CH2CHC(O) & C(CH3)2), 1.87–1.09 (128H, m, CH2CHC(O)
& CH2CH2CH2CH2CH2CH2CH2CH2CH2CH2CH3), 0.83–0.72 (5H, m,
CH2CH3)
PHEA72 — 𝛿H (300 MHz, D2O) 8.30–7.96 (34H, m, NH), 3.96–3.52
(126H, m, NHCH2), 3.52–3.07 (155H, m, CH2OH & SCH2), 2.36–1.88
(70H, m, CH2CHC(O) & C(CH3)2), 1.88–1.03 (148H, m, CH2CHC(O)
& CH2CH2CH2CH2CH2CH2CH2CH2CH2CH2CH3), 0.82–0.70 (5H, m,
CH2CH3)
PHEA110 — 𝛿H (300 MHz, D2O) 8.24–8.02 (28H, m, NH), 3.83–3.51
(239H, m, NHCH2), 3.51–3.08 (293H, m, CH2OH & SCH2), 2.40–1.90
(117H, m, CH2CHC(O) & C(CH3)2), 1.90–1.03 (273H, m, CH2CHC(O)
& CH2CH2CH2CH2CH2CH2CH2CH2CH2CH2CH3), 0.86–0.73 (5H, m,
CH2CH3)
Representative Poly(N-Hydroxyethyl Acrylamide) (PHEA40) Glycan Func-
tionalization: 0.25 g (0.088 mmol) of poly(2-hydroxyethyl acrylamide)
and 0.090 g (0.50 mmol) of galactosamine HCl were added to 25 mL
of DMF containing 0.05 M m TEA. The reaction was stirred at 50 °C for
16 h. Solvent was removed under vacuum. The crude product was dis-
solved in the minimum amount of methanol at RTP before cooling in a
liquid nitrogen bath. Diethyl ether cooled in liquid nitrogen was added
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to the methanol to form a precipitate. The mixture was centrifuged for
2 min at 13 krpm and the liquid decanted off. The solid was dissolved
in methanol and removed under vacuum to give an orange/brown crys-
talline solid. 𝛿H (300 MHz, D2O) 8.03–7.86 (6H, m, NH), 4.96–4.87
(2H, anomeric protons), 4.13–3.51 (≈90H, m, NHCH2 & glycan pro-
tons), 3.51–3.09 (≈80H, m, CH2OH & SCH2 & glycan protons), 2.47–1.90
(≈50H, m, CH2CHC(O), C(CH3)2 & glycan protons), 1.90–1.42 (98H, m,
CH2CHC(O) & CH2CH2CH2CH2CH2CH2CH2CH2CH2CH3), 0.93–0.72
(5H, m, CH2CH3). FTIR (cm
−1) — 3267 (OH, broad), 3094 & 2926
(C(O)NH and NH), 1638 & 1545 (C(O)NH).
Representative Poly(2-Hydroxyethyl Acrylamide) (PHEA40) PFP Removal
with n-Pentylamine: 0.4 g (0.14 mmol) of poly(2-hydroxyethyl acrylamide)
and 0.05 mL (3.28 mmol) of n-pentylamine were added to 40 mL of DMF
containing 0.05 M TEA. The reaction was stirred at 50 °C for 16 h. Solvent
was removed under vacuum. The crude product was dissolved in the min-
imum amount of methanol at RTP before cooling in a liquid nitrogen bath.
The crude product was dissolved in the minimum amount of methanol.
Diethyl ether cooled in liquid nitrogen was added to the methanol to form
a precipitate. The mixture was centrifuged for 2 min at 13 krpm and the
liquid decanted off. The solid was dissolved in methanol and removed un-
der vacuum to give a pale yellow crystalline solid. Removal of PFP was
determined by 19F NMR.
Gold Nanoparticle Polymer Coating Functionalization—16 nm: 100 mg
of glycopolymer was agitated overnight with 10 mL of 16 nm AuNPs
≈1 Abs at UVmax. The solution was centrifuged at 13 krpm for 30 min and
the pellet resuspended in 10 mL of water; the solution was centrifuged
again at 13 krpm for 30 min and the pellet resuspended in 1 mL aliquots
and centrifuged at 14.5 krpm for 10 min. The pellets were combined into
a 1 mL solution with an absorbance at 520 nm of ≈10 Abs.
Gold Nanoparticle Polymer Coating Functionalization—40 nm: 100 mg
of glycopolymer was agitated overnight with 10 mL of 40 nm AuNPs
≈1 Abs at UVmax. The solution was centrifuged at 8 krpm for 30 min and
the pellet resuspended in 10 mL of water, the solution was centrifuged
again at 8 krpm for 30 min and the pellet resuspended in 1 mL aliquots
and centrifuged at 8 krpm for 10 min. The pellets were combined into a
1 mL solution with an absorbance at UVmax of ≈10 Abs.
Summary of Lateral Flow Strip Running Protocol and Analysis: Test lines
were added and dried onto the dipsticks; in flow-through, the analyte was
deposited in place of a test line.
50 μL of running buffer (either with or without analyte) was agitated
on a roller for 5 min. 45 μL of running buffer was added to a PCR tube;
a dipstick was added to the tube, so the dipstick protruded from the
top and the immobile phase (1 cm from nonwick end) was not below
the solvent line. There was one test per tube and each test was run for
20 min before drying at room temperature for 5 min. All tests were run in
triplicate.
The cassette running followed a similar procedure but used a total vol-
ume of 80 μL of running buffer and the tests run for 10 min before analysis
of the triplicates.
A more detailed summary of dipstick and cassette manufacture, run-
ning, and analysis can be found in the Supporting Information.
Statistical Analysis: All strips (dipsticks) and cassettes were run in trip-
licate.
All strips were attached to an acetate sheet and scanned using a
Kyocera TASKalfa 5550ci printer to a pdf file that was converted to a
jpeg; scans were taken within 1 h of strip drying. The jpeg was analyzed
in ImageJ 1.51[48] using the plot profile function to create a data set
exported to Microsoft Excel for Mac. The data was exported to Origin
2019 64Bit and trimmed to remove pixel data not from the strip surface.
The data was aligned and averaged (mean). The data was then reduced
by number of groups to 100 data points (nitrocellulose and wick) and
plotted as grey value (scale) versus relative distance along the 100 data
points.
Signal to noise was determined for the strips as follows. Relative
distance pixel 15–35 (area around the test line) was averaged (mean) to
provide average noise around the test line for strips versus Galɑ1-3Gal𝛽1-
4GlcNAc-BSA (BSA-Gal) (1 mg mL−1) as a test line. The signal value was
determined by selecting the lowest grey value between 15 and 35 relative
distance pixels as a test line. Equation S1, Supporting Information, was
then used to determine the signal to noise ratio.
Signal intensity was determined for the strips as follows. Relative
distance pixel 15–35 (area around the test line), excluding pixels that
contributed to the signal peak were averaged (mean). This average was
subtracted from the lowest grey value between 15 and 35.
Signal intensity was determined for the cassettes as follows. Relative
distance pixel 1–10 and 51–60 (area around the test line), excluding pixels
that contributed to the signal peak were averaged (mean). This average
was subtracted from the lowest grey value between 11 and 50 (test line
region).
Supporting Information
Supporting Information is available from the Wiley Online Library or from
the author.
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